Discouraging signs for Eisai's Alzheimer's candidate BAN2401

Japanese and US pharma majors Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have reported that Study 201, investigating Alzheimer’s candidate BAN2401, has not reached its primary endpoint after 12 months.

The efficacy of five dose groups of BAN2401 was evaluated at 12 months based on Eisai’s in-house developed novel endpoint Alzheimer’s disease Composite Score (ADCOMS). None of the groups reached the predefined efficacy endpoint.

The blinded study will continue, and the firms hope that a final analysis at 18 months will demonstrate clinically-significant results. Final data will arrive mid-2018.